About Imagion Biosystems
Imagion’s MagSense® technology has the potential to provide more specific and sensitive detection for cancer than current imaging technologies. By using tiny magnetic nanoparticles to identify tumors, our MagSense® technology does not require use of radioactivity, making it a safer alternative for non- invasive detection.
Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
Corporategovernance
Imagion Biosystems and its Board of Directors is committed to maintain high levels of integrity and ethical standards in the way we conduct our business and in our corporate governance.
The Board of Directors is composed, chiefly, of non-executive directors with the Chairman having been elected by the full Board. The company is small, and accordingly, the Board has adopted those policies it deems prudent to protect the interests of our shareholders without being overly burdensome on the company.
Investor services
Investors seeking information regarding their shareholding or dividends or wishing to advise of a change of address should contact Boardroom Pty Limited at:
Boardroom Pty Limited
Level 12, 225 George Street,
Sydney, NSW, 2000
Telephone: (02) 9290 9600 Facsimile: (02) 9279 0664 or
Visit the online service at www.boardroomlimited.com.au
Boardroom Pty Limited has an online service for investors called InvestorServe. This enables investors to make online changes, view balances and transaction history, as well as obtain information about recent dividend payments and download various forms to assist in the management of their holding.
Questions?
Reach the Investor Relations department by emailing investor@imagionbio.com, and we’ll get back to you.